<DOC>
	<DOCNO>NCT00010075</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one chemotherapy drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat old woman metastatic breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Older Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine survival without degradation quality life elderly woman metastatic breast cancer treat leucovorin calcium , fluorouracil , mitoxantrone . - Determine efficacy regimen , term response survival without progression , patient . - Determine tolerance patient regimen . OUTLINE : This multicenter study . Patients receive mitoxantrone IV leucovorin calcium IV 2 hour day 1 . Patients receive fluorouracil IV 46 hour day 1-2 . Treatment repeat every 21 day maximum 8 course absence disease progression unacceptable toxicity . Quality life assess baseline , 3 course , treatment completion . Patients follow every 3 month . PROJECTED ACCRUAL : A total 39 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma breast Bidimensionally measurable evaluable disease At least one nonirradiated lesion least 2 cm great diameter OR Serous drainage , cutaneous metastasis , osseous metastasis , etc . No symptomatic cerebral metastasis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 75 90 Sex : Female Menopausal status : Postmenopausal Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Platelet count least 100,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Hepatic : Alkaline phosphatase less 3 time normal Bilirubin le 1.5 time normal Transaminases le 3 time normal Total protein great 60 % Albumin great 30 g/L Renal : Creatinine clearance great 60 mL/min Cardiovascular : LVEF great 50 % echocardiogram scintigraph ECG normal No uncontrolled angina No myocardial infarction within past 6 month Other : No medical illness condition would preclude study No prior malignancy except basal cell skin cancer curatively treat carcinoma situ cervix No psychological , social , familial , geographical reason would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior adjuvant chemotherapy allow No prior adjuvant anthracyclines No prior chemotherapy metastatic disease Endocrine therapy : One two prior regimen hormonal therapy allow metastatic disease Radiotherapy : No prior radiotherapy metastatic disease Surgery : Not specify Other : No concurrent participation another study</criteria>
	<gender>Female</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2003</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>